Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:219-220 (4 August), doi:10.1136/bmj.39272.445428.80 (published 11 July 2007)
Further evidence on the early benefits and late risks does not change advice to menopausal women
| The first 150 words of the full text of this article appear below. |
The publication of the combined treatment arm of the women's health initiative study in July 2002 led to a dramatic fall in the use of hormone replacement therapy and a revision of the package insert for all hormone therapy preparations. This clinical trial randomised 16 608 women, aged 50-79 years, to 0.625 mg conjugated equine oestrogen and 2.5 mg medroxyprogesterone acetate or placebo.1 The study was stopped early, at an average follow-up of 5.2 years, because analysis did not find the expected benefit in preventing coronary heart disease. In addition, the global index score—which measures the balance between benefit and harm—showed that the benefits in preventing hip fracture and colorectal cancer were outweighed by the increased risk of breast cancer, stroke, and deep vein thrombosis.
This week's BMJ sees the publication of the women's international study of long duration oestrogen after menopause by Vickers and colleagues.2 This study was originally
Helen Roberts, senior lecturer in women's health
Department of Obstetrics and Gynaecology, University of Auckland, Private Bag 92019, Auckland, New Zealand 1142
h.roberts@auckland.ac.nz
Read all Rapid Responses